Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142323 |
| CAS No | NA |
| Mol.F. | C16H18N4O5S |
| Mol.Wt. | 378.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142324 |
| CAS No | NA |
| Mol.F. | C16H18N4O5S |
| Mol.Wt. | 378.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142325 |
| CAS No | NA |
| Mol.F. | C16H20N4O6S |
| Mol.Wt. | 396.42 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142326 |
| CAS No | NA |
| Mol.F. | C24H25N5O6S |
| Mol.Wt. | 511.55 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142327 |
| CAS No | NA |
| Mol.F. | C15H20N4O4S |
| Mol.Wt. | 352.41 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142328 |
| CAS No | NA |
| Mol.F. | C16H13N3O3 |
| Mol.Wt. | 295.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142329 |
| CAS No | NA |
| Mol.F. | C13H19N3O5S |
| Mol.Wt. | 329.37 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142330 |
| CAS No | NA |
| Mol.F. | C13H16N2O4 |
| Mol.Wt. | 264.28 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142331 |
| CAS No | NA |
| Mol.F. | C32H37N7O9S2 |
| Mol.Wt. | 727.81 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142332 |
| CAS No | NA |
| Mol.F. | C32H38N8O11S2 |
| Mol.Wt. | 774.82 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142333 |
| CAS No | NA |
| Mol.F. | C48H55N11O14S3 |
| Mol.Wt. | 1106.21g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142334 |
| CAS No | NA |
| Mol.F. | C31H38N8O9S2 |
| Mol.Wt. | 730.81 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142335 |
| CAS No | NA |
| Mol.F. | C48H56N12O16S3 |
| Mol.Wt. | 1153.22 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142336 |
| CAS No | NA |
| Mol.F. | C17H20N4O7S |
| Mol.Wt. | 424.43 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142337 |
| CAS No | NA |
| Mol.F. | C21H18N4O4S |
| Mol.Wt. | 422 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142338 |
| CAS No | NA |
| Mol.F. | C8H11N3O4S |
| Mol.Wt. | 245.25 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |